Michael D George1,2, Joshua F Baker3,4, Alexis Ogdie3,4. 1. From the University of Pennsylvania, Division of Rheumatology, and Perelman School of Medicine, Department of Biostatistics, Epidemiology, and Informatics; Philadelphia Veterans Affairs Medical Center, Division of Rheumatology, Philadelphia, Pennsylvania, USA. Michael.george@uphs.upenn.edu. 2. M.D. George, MD, MSCE, Instructor, University of Pennsylvania, Division of Rheumatology; J.F. Baker, MD, MSCE, Assistant Professor, Philadelphia VA Medical Center, Division of Rheumatology, and University of Pennsylvania; A. Ogdie, MD, MSCE, Assistant Professor, University of Pennsylvania, Division of Rheumatology, and Perelman School of Medicine, Department of Biostatistics, Epidemiology, and Informatics. Michael.george@uphs.upenn.edu. 3. From the University of Pennsylvania, Division of Rheumatology, and Perelman School of Medicine, Department of Biostatistics, Epidemiology, and Informatics; Philadelphia Veterans Affairs Medical Center, Division of Rheumatology, Philadelphia, Pennsylvania, USA. 4. M.D. George, MD, MSCE, Instructor, University of Pennsylvania, Division of Rheumatology; J.F. Baker, MD, MSCE, Assistant Professor, Philadelphia VA Medical Center, Division of Rheumatology, and University of Pennsylvania; A. Ogdie, MD, MSCE, Assistant Professor, University of Pennsylvania, Division of Rheumatology, and Perelman School of Medicine, Department of Biostatistics, Epidemiology, and Informatics.
Abstract
OBJECTIVE: The role of methotrexate (MTX) for the treatment of spondyloarthritis (SpA) remains uncertain. Aims were to compare MTX and tumor necrosis factor inhibitor (TNFi) persistence in spondyloarthritis versus rheumatoid arthritis (RA) and to determine whether concomitant conventional synthetic disease-modifying antirheumatic drug (csDMARD) use is associated with improved TNFi persistence in SpA. METHODS: This retrospective cohort study using Optum's deidentified Clinformatics Data Mart Database 2000-2014 identified patients with RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) without prior biologic use who were initiating MTX or a TNFi. Cox proportional hazards models compared time to medication discontinuation over the next 2 years between patients with RA, PsA, or AS, adjusting for potential confounders. In similar analyses stratified by disease, Cox models were used to assess whether concomitant use of csDMARD was associated with TNFi persistence. RESULTS: We identified 31,527 MTX initiators (26,708 RA, 2939 PsA, 1880 AS) and 34,651 TNFi initiators (24,134 RA, 6705 PsA, 3812 AS). MTX was discontinued sooner in patients with PsA [adjusted HR (aHR) 1.10, 95% CI 1.04-1.16] and AS (aHR 1.23, 1.16-1.31) versus RA, while TNFi were discontinued at similar rates in RA and AS and discontinued later in PsA (aHR 0.93, 0.89-0.97). Concomitant use of MTX (compared to no csDMARD) was associated with lower rates of TNFi discontinuation in RA (aHR 0.85, 0.80-0.89), PsA (aHR 0.81, 0.74-0.89), and AS (aHR 0.79, 0.67-0.93). CONCLUSION: MTX discontinuation occurs sooner in patients with PsA and AS versus RA. Concomitant use of MTX with a TNFi, however, is associated with improved TNFi persistence in all 3 diseases.
OBJECTIVE: The role of methotrexate (MTX) for the treatment of spondyloarthritis (SpA) remains uncertain. Aims were to compare MTX and tumor necrosis factor inhibitor (TNFi) persistence in spondyloarthritis versus rheumatoid arthritis (RA) and to determine whether concomitant conventional synthetic disease-modifying antirheumatic drug (csDMARD) use is associated with improved TNFi persistence in SpA. METHODS: This retrospective cohort study using Optum's deidentified Clinformatics Data Mart Database 2000-2014 identified patients with RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) without prior biologic use who were initiating MTX or a TNFi. Cox proportional hazards models compared time to medication discontinuation over the next 2 years between patients with RA, PsA, or AS, adjusting for potential confounders. In similar analyses stratified by disease, Cox models were used to assess whether concomitant use of csDMARD was associated with TNFi persistence. RESULTS: We identified 31,527 MTX initiators (26,708 RA, 2939 PsA, 1880 AS) and 34,651 TNFi initiators (24,134 RA, 6705 PsA, 3812 AS). MTX was discontinued sooner in patients with PsA [adjusted HR (aHR) 1.10, 95% CI 1.04-1.16] and AS (aHR 1.23, 1.16-1.31) versus RA, while TNFi were discontinued at similar rates in RA and AS and discontinued later in PsA (aHR 0.93, 0.89-0.97). Concomitant use of MTX (compared to no csDMARD) was associated with lower rates of TNFi discontinuation in RA (aHR 0.85, 0.80-0.89), PsA (aHR 0.81, 0.74-0.89), and AS (aHR 0.79, 0.67-0.93). CONCLUSION: MTX discontinuation occurs sooner in patients with PsA and AS versus RA. Concomitant use of MTX with a TNFi, however, is associated with improved TNFi persistence in all 3 diseases.
Authors: Erik H Vogelzang; Eva L Kneepkens; Michael T Nurmohamed; Arno W R van Kuijk; Theo Rispens; Gertjan Wolbink; Charlotte L M Krieckaert Journal: Ann Rheum Dis Date: 2014-08-12 Impact factor: 19.103
Authors: Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield Journal: Arthritis Rheum Date: 2012-09
Authors: Alexis Ogdie; YiDing Yu; Kevin Haynes; Thorvardur Jon Love; Samantha Maliha; Yihui Jiang; Andrea B Troxel; Sean Hennessy; Steven E Kimmel; David J Margolis; Hyon Choi; Nehal N Mehta; Joel M Gelfand Journal: Ann Rheum Dis Date: 2014-10-28 Impact factor: 19.103
Authors: Philip J Mease; Alan J Kivitz; Francis X Burch; Evan L Siegel; Stanley B Cohen; Peter Ory; David Salonen; Joel Rubenstein; John T Sharp; Wayne Tsuji Journal: Arthritis Rheum Date: 2004-07
Authors: L Gossec; J S Smolen; S Ramiro; M de Wit; M Cutolo; M Dougados; P Emery; R Landewé; S Oliver; D Aletaha; N Betteridge; J Braun; G Burmester; J D Cañete; N Damjanov; O FitzGerald; E Haglund; P Helliwell; T K Kvien; R Lories; T Luger; M Maccarone; H Marzo-Ortega; D McGonagle; I B McInnes; I Olivieri; K Pavelka; G Schett; J Sieper; F van den Bosch; D J Veale; J Wollenhaupt; A Zink; D van der Heijde Journal: Ann Rheum Dis Date: 2015-12-07 Impact factor: 19.103
Authors: Elisabeth Lie; Désirée van der Heijde; Till Uhlig; Marte S Heiberg; Wenche Koldingsnes; Erik Rødevand; Cecilie Kaufmann; Knut Mikkelsen; Tore K Kvien Journal: Ann Rheum Dis Date: 2009-09-09 Impact factor: 19.103
Authors: Philip J Mease; Dafna D Gladman; David H Collier; Christopher T Ritchlin; Philip S Helliwell; Lyrica Liu; Gregory Kricorian; James B Chung Journal: Arthritis Rheumatol Date: 2019-05-28 Impact factor: 10.995